Predictors of Long-Term Disease Control and Survival for HER2-Positive Advanced Breast Cancer Patients Treated With Pertuzumab, Trastuzumab, and Docetaxel

Overview of attention for article published in Frontiers in oncology, August 2019

Altmetric Badge

About this Attention Score

Average Attention Score compared to outputs of the same age
Good Attention Score compared to outputs of the same age and source (66th percentile)

Mentioned by

twitter: 3 X users

Citations

dimensions_citation: 9 Dimensions

Readers on

mendeley: 30 Mendeley

Summary X Dimensions citations

So far, Altmetric has seen 4 X posts from 3 X users, with an upper bound of 8,473 followers.

RT @pmg_flinders: Predictors of Long-Term Disease Control and Survival for HER2-Positive Advanced Breast Cancer Patients Treated With Pertu…

13 Jan 2020

Reply Repost Favourite

Predictors of Long-Term Disease Control and Survival for HER2-Positive Advanced Breast Cancer Patients Treated With Pertuzumab, Trastuzumab, and Docetaxel #cancerresearch #breastcancer #precisionmedicine @cancerFCIC @Flinders @FrontOncology @FlindersLib h

09 Jan 2020

Reply Repost Favourite

Predictors of Long-Term Disease Control and Survival for HER2-Positive Advanced Breast Cancer Patients Treated With Pertuzumab, Trastuzumab, and Do... - PubMed - NCBI https://t.co/wyGQeoQGNG

18 Sep 2019

Reply Repost Favourite

New research: Predictors of Long-Term Disease Control and Survival for HER2-Positive Advanced Breast Cancer Patients Treated With Pertuzumab, Trastuzumab, and Docetaxel: Background HER2-positive advanced breast cancer (ABC) is associated with… https://t.co

23 Aug 2019

Reply Repost Favourite

This page shows the most recent X posts that mention this research output.

Click here to find out how to access more activity.